Paramita Ray
Associate Research Scientist
Radiation Oncology
Department of Radiation Oncology
1301 Catherine Street, Med Sci 1, RM 4311
Ann Arbor, MI 48109
[email protected]

Available to mentor

Paramita Ray
Associate Research Scientist
  • About
  • Qualifications
  • Research Overview
  • Recent Publications
  • About

    Dr. Ray has over 10 years of research experience in the field of cell and developmental biology. She obtained her PhD in 2007 from the Department of Biological Sciences at the University of Illinois at Chicago (UIC), where she studied the neurodevelopment of Caenorhabditis elegans. During her postdoctoral studies she became interested in cancer biology where she studied the role of chemokine receptors (CXCR4 and CXCR7) in breast cancer metastasis. As a Research Investigator in the Department of Radiation Oncology she studies factors that regulate the stability of various oncoproteins including Epidermal Growth Factor Receptor (EGFR) and mutant KRAS. She is also actively involved in collaborative research identifying ubiquitin ligases (E3s) responsible for regulating protein stabilities of various oncogenes including mutant TP53 and CYP24A1.

    Qualifications
    • Postdoctoral Research Associate
      Northwestern University, Chicago, 2008
    Research Overview

    Factors regulating EGFR protein stability.
    Oncogenic potential of CYP24A1 in lung cancer progression.
    Understanding the role of GRAIL in Barrett’s progression to esophageal adenocarcinoma (EAC).

    Recent Publications See All Publications
    • Journal Article
      GRAIL1 Stabilizes Misfolded Mutant p53 through a Ubiquitin Ligase-Independent, Chaperone Regulatory Function.
      Ray P, Jaiswal S, Ferrer-Torres D, Wang Z, Nancarrow D, Curtin M, Martinho MS, Lacy SM, Kasturirangan S, Thomas D, Spence JR, Truttmann MC, Lagisetty KH, Lawrence TS, Wang TD, Beer DG, Ray D. Mol Cancer Res, 2024 Nov 1; 22 (11): 996 - 1010. DOI:10.1158/1541-7786.MCR-24-0361
      PMID: 39018356
    • Journal Article
      ISG15/GRAIL1/CD3 axis influences survival of patients with esophageal adenocarcinoma.
      McEwen DP, Ray P, Nancarrow DJ, Wang Z, Kasturirangan S, Abdullah S, Balan A, Hoskeri R, Thomas D, Lawrence TS, Beer DG, Lagisetty KH, Ray D. JCI Insight, 2024 May 23; 9 (13): DOI:10.1172/jci.insight.179315
      PMID: 38781019
    • Presentation
      Radiosensitization of esophageal adenocarcinoma cells: importance of DNAJA1 and ISG15 targeting
      Ray P. 2023 Mar 22;
    • Presentation
      RNF128 Iso1 cooperates with mutant p53 in Barrett's progression
      Ray P. 2022 Aug 18;
    • Journal Article
      Improved prediction of radiation pneumonitis by combining biological and radiobiological parameters using a data-driven Bayesian network analysis
      Tonaye H, David K, Ming T, Ralph J, Yi L, Philip B, Yilun S, Erin S, Ray P, Christopher M, Martha M, Matthew JS, Michael G, Shirish MG, Gregory AY, Muneesh T, Issam EN, Caitlin AS, Randall TH, Shruti J, Theodore SL, Dipankar R. Translational Oncology, 2022 Apr 11; 21:
    • Journal Article
      UBCH5 Family Members Differentially Impact Stabilization of Mutant p53 via RNF128 Iso1 During Barrett's Progression to Esophageal Adenocarcinoma.
      Ray P, Nancarrow DJ, Ferrer-Torres D, Wang Z, San Martinho M, Hinton T, Wu JH, Wu A, Turgeon DK, Hammer MA, Dame MK, Lawrence TS, O'Brien PJ, Spence JR, Beer DG, Ray D. Cell Mol Gastroenterol Hepatol, 2022 13 (1): 129 - 149. DOI:10.1016/j.jcmgh.2021.08.003
      PMID: 34416429
    • Proceeding / Abstract / Poster
      UBCH5 Family Members Differentially Impact Stabilization of Mutant p53 via RNF128 Iso1 During Barrett's Progression to Esophageal Adenocarcinoma
      Ray P, Derek JN, Daysha F-T, Zhuwen W, May SM, Tonaye H, Joshua W, Angeline W, Danielle KT, Max AH, Michael KD, Theodore SL, Patrick JO, Jason RS, David GB, Dipankar R. Cellular and Molecular Gastroenterology and Hepatology, 2021 Aug 17; 13 (1): 129 - 149. DOI:10.1016/j.jcmgh.2021.08.003
    • Presentation
      RNF128 Iso1-Mutant p53 Cooperation in Barrett's Progression
      Ray P. 2021 May 5;